statistics

Killer statistician

In the field of statistics, we need specific skills necessary for being successfull. Debarshi Dey, currently the head of the Statistics and Programming and Data Management department at Morphosys, has spent the past 13 years in the pharmaceutical industry. With a PhD in statistics from UC Riverside, Debarshi believes that to be a “killer statistician,” one must adopt the roles of a detective, lawyer, and storyteller.  Debarshi and I discuss these key characteristics that make a statistician effective. We also explore these key takeaways from our conversation:

Deep work

Today I’m talking with Rachel Tham, a principal statistician, about a book that has been incredibly impactful in both of our lives—Deep Work. We discuss what deep work is and how it can help statisticians at work.  Deep work is a concept developed by Cal Newport which encourages people to focus intensely on one task for an extended period of time without any distractions. This type of focused work allows people to produce higher-quality results in less time than if they were trying to multitask or do shallow tasks. Join us and learn more about deep work concepts and how they …

Deep work Read More »

What will be the role of health economics in the future EU HTA?

Are you a statistician working in the pharmaceutical industry and never got in touch with economic modelling and network meta-analyses? Then you should listen to this episode! The EU HTA will not only affect all statisticians in the pharmaceutical industry with respect to skill sets and collaboration (we talked about that in podcast #3), but will also have an impact on the economic modeling that is needed for the reimbursement and pricing decisions in many European countries. Understanding the influence of the joint clinical assessment on economic modeling, the relationship between estimands and PICOs as well as the pre-specification of statistical …

What will be the role of health economics in the future EU HTA? Read More »

Future implications of EU HTA and how Next Gen get involved

All statisticians in the Pharmaceutical Industry will be impacted by the new EU HTA regulation. Activities around HTA submissions will happen earlier than currently, in parallel to the regulatory approval process for marketing authorization. There will be an increased scope of evidence for the joint clinical assessment to fulfill the needs of all EU member states, and so there will be a large package of statistical analyses that need to be provided in addition to the submission to the regulatory bodies. This will redefine how you, as a statistician, work, and with whom you need to collaborate. Both HTA and clinical …

Future implications of EU HTA and how Next Gen get involved Read More »

What is the role of estimands in the EU HTA?

If you’re a statistician working in a regulatory setting, you’re probably familiar with estimands as a way to frame the clinical question of interest. But what’s the role of estimands beyond regulatory approval, in a Health Technology Assessment setting? That question is especially important these days where the framework for pan-European HTA is taking shape. In this episode, we’ll touch on some HTA body views around estimands, and reflect on how current draft guidelines for EU HTA do and don’t address estimands.

First mover advantage and how it applies to statistics

Why is it important for a statistician to take the culture of the first mover advantage on a more personal level? How do the first-mover advantages help the personal and professional growth of a statistician? What does it take to be the first mover? How does being the first mover solve problems early? How do you develop the motivation to be the first mover? In this conversation, we talk about the effective impact of the first-mover advantage. To give a more visual distinction of this strategy, it is more like a chess game where the first mover often decides the direction …

First mover advantage and how it applies to statistics Read More »